| CASE REPORT |
|
| Year : 2020 | Volume
: 65
| Issue : 3 | Page : 214-216 |
|
|
Nivolumab-induced bullous pemphigoid managed without drug withdrawal
Mónica Munera-Campos, Adrià Plana-Pla, Noelia Rivera, Aram Boada, Carlos Ferrándiz
Department of Dermatology, Germans Trias I Pujol University Hospital, Universitat Autònoma De Barcelona, Badalona, Spain
Correspondence Address:
Mónica Munera-Campos
Department of Dermatology, Germans Trias I Pujol University Hospital, Universitat Autonoma De Barcelona, Carretera De Canyet, S/N, 08916 Badalona, Barcelona
Spain
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/ijd.IJD_321_18
|
|
|
The widespread use of anti-programmed cell death receptor-1 (PD-1) agents has shed light to unusual immune-related adverse effects, especially affecting the skin. We report a case of bullous pemphigoid secondary to nivolumab therapy for metastatic renal carcinoma with a previously unreported complete response to clobetasol ointment alone. The autoimmune blistering disease was successfully treated without oral corticosteroids, and the anti-PD-1 agent could be maintained without recurrence of the skin lesions. Topical therapy remains a good option in selected, mild-to-moderate cases of induced bullous pemphigoid.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
